Ricky Turgeon

Pharmacy practice, Cardiovascular disease, Decision-making, Clinical pharmacy, Heart failure. Dr. Turgeon’s research focuses on integrating evidence and shared decision-making into clinical practice to optimize the care of people living with cardiovascular disease. His clinical focus is in optimal use of heart failure pharmacotherapy, medication safety in cardiovascular disease, and medications to reduce cardiovascular risk (e.g., antithrombotic, lipid-lowering, and antihypertensive medications). His group uses various methods, including observational designs (cohort or case-control study using administrative data and clinical registries), clinical prediction model development and validation, pragmatic randomized controlled trials, and evidence syntheses (systematic reviews with or without meta-analyses, scoping reviews, and modeling studies) to address important clinical questions in cardiovascular pharmacotherapy.

[2023] Bainey K, Marquis-Gravel G, Belley-Côté E, Turgeon RD, et al. 2023 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Can J Cardiol 2023[online]. Available at: https://onlinecjc.ca/article/S0828-282X(23)01841-X/fulltext [2023] Beauchesne ABM, Koshman SK, Beavers CJ, Gorman SK, Turgeon RD. Defining pharmacist activities in ambulatory heart failure clinics: North American survey and modified Delphi study. J Am Coll Clin Pharm 2023;6:1180–90. Available at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1855 [2023] MacDonald BJ, Turgeon RD. Incorporation of Shared Decision-Making in International Cardiovascular Guidelines, 2012–2022. JAMA Network Open 2023;6:e2332793. doi: